Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term

Novo Nordisk (NVO) is highlighted as a compelling growth stock by Zacks, despite holding a #3 (Hold) rank, due to its top-tier 'A' scores for both Growth Style and VGM. The global healthcare leader, prominent in diabetes and other therapeutic areas, is projected for 17.7% year-over-year earnings growth for the current fiscal year. This outlook is supported by recent upward revisions from three analysts for fiscal 2025 estimates, which currently stand at a Zacks Consensus Estimate of $3.86 per share, alongside a consistent +3.2% average earnings surprise, positioning NVO as a noteworthy consideration for growth-focused investors.

Analysis

According to Zacks' proprietary rating system, Novo Nordisk (NVO) presents a compelling case for growth investors despite its neutral #3 (Hold) rank. The company's strong fundamentals are underscored by top-tier 'A' ratings for both its Growth Style Score and its composite VGM Score. This positive assessment is supported by a forecasted 17.7% year-over-year earnings growth for the current fiscal year and a consistent history of beating expectations, as evidenced by an average earnings surprise of +3.2%. While three analysts have revised their fiscal 2025 earnings estimates higher in the last 60 days, indicating strengthening sentiment, the Zacks Consensus Estimate for that period has remained stable at $3.86 per share. This suggests that the broader market consensus may not yet fully reflect the most recent positive analyst outlooks, positioning NVO as a prominent player in high-growth therapeutic areas like diabetes and obesity with potentially under-appreciated forward momentum.

Key Decisions for Investors

• Growth-oriented investors should consider the strong underlying fundamentals, such as the projected 17.7% earnings growth and 'A' Growth Score, which may outweigh the cautionary signal of the neutral Zacks #3 'Hold' rank.
• Investors should monitor for a potential upgrade to the Zacks Rank or an upward revision in the consensus earnings estimate, as recent positive analyst revisions suggest sentiment could be turning more bullish.
• Given the 'Hold' rating, which indicates a lack of immediate catalysts from earnings estimate trends, a strategy of holding existing positions or gradually building a new one may be prudent while awaiting further confirmation of upward momentum.